

# ESMO'24 CRC Abstracts of Interest



BARCELONA 2024 **ESMO** congress

BARCELONA SPAIN  
13-17 SEPTEMBER 2024



## Anchor Point Insight:

The alarming rise in colorectal cancer (CRC) rates among young adults in the past few decades, along with CRC's high mortality rate, highlight the urgent need for new treatment options. New and updated data at the 2024 ESMO Congress highlight potential therapeutic advances across the CRC treatment landscape.



Anchor Point  
Insights



# ESMO'24 CRC Abstracts of Interest

**The efficacy and safety of ivonescimab with or without ligufalimab in combination with FOLFOXIRI as first-line (1L) treatment for metastatic colorectal cancer (mCRC)**

Yanhong Deng, MD, PhD

ESMO #514MO

## Anchor Point Insight:

A first-in-class VEGF $\times$ PD-1 bsAb, Akeso/Summit Therapeutics' ivonescimab, has previously demonstrated statistically significant improvement head-to-head compared to pembrolizumab in a Ph3 trial in NSCLC. Ivonescimab, both alone and in combination with ligufalimab (CD47 mAb), along with chemotherapy showed promising efficacy (9-mos PFS rate: 81.4% - 86.2%) in the difficult 1L microsatellite stable (MSS) mCRC setting.





# ESMO'24 CRC Abstracts of Interest

## Amivantamab plus FOLFOX or FOLFIRI in metastatic colorectal cancer: Results from OrigAMI-1, an open-label, phase Ib/II study

Filippo Pietrantonio, MD

ESMO #513MO

### Anchor Point Insight:

J&J's amivantamab (EGFRxMET bsAb) is currently approved in multiple NSCLC indications globally with ongoing trials in additional solid tumor indications. This first data in combination with chemotherapy in mCRC demonstrated promise (best timepoint response: 63% for ami+FOLFOX) in an indication of high unmet need.





# ESMO'24 CRC Abstracts of Interest

**Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C–mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase Ib CodeBreak 101 study**

Salvatore Siena, MD

ESMO #5050

## Anchor Point Insight:

In recent years, KRAS mutations have gone from “undruggable” to promising targets, although challenges remain. Sotorasib is the first KRAS-G12C inhibitor approved by the FDA, but data to date from CodeBreak 101 in mCRC has lagged competitors. This first data in 1L mCRC showed a confirmed ORR of 75.0% for the combination of sotorasib, panitumumab, and FOLFIRI.





# ESMO'24 CRC Abstracts of Interest

**Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)**

Wungki Park, MD, MS

ESMO #6080

## Anchor Point Insight:

In recent years, KRAS mutations have gone from “undruggable” to promising targets, although challenges remain. ASP3082, a first-in-class KRAS G12D degrader, represents an interesting approach to targeting KRAS as both a novel isotype specific (KRAS-G12D) molecule as well as a protein degrader compared to an inhibitor, although early efficacy offers little differentiation.





# ESMO'24 CRC Abstracts of Interest

**Noadjuvant nivolumab (nivo) plus relatlimab (rela) in MMR-deficient colon cancer: Results of the NICHE-3 study**

Peter G. De Gooyer

ESMO #5030

**IMHOTEP Phase II trial of neoadjuvant pembrolizumab in dMMR/MSI tumors: Results of the colorectal cancer cohort**

Christelle de la Fouchardiere, MD

ESMO #5040

## Anchor Point Insight:

Noadjuvant checkpoint inhibition (CPI) has previously demonstrated highly promising efficacy in dMMR-deficient CRC (~10-15% of total CRC cases), including a 100% response rate for the combination of nivolumab and ipilimumab in the Ph2 NICHE trial. Updated data from NICHE-3 and IMHOTEP supports use of CPI's in the neoadjuvant setting, but also highlights treatment questions (need for organ-sparing strategies, optimal number of cycles, etc.).

